Compare Bristol-Myers Squibb Co (BMY) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs VanEck Rare Earth/Strategic Metals — how do they compare? Bristol-Myers Squibb Co trades at $63.79 (market cap $129.94B), while VanEck Rare Earth/Strategic Metals trades at $77.2. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while VanEck Rare Earth/Strategic Metals pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.
| BMY | REMX | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $65.89 | $109.53 |
52-Week Low | $42.60 | $56.60 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $77.24, down 1.54% with a bullish technical signal supported by moving averages. The ETF provides exposure to 38 global rare earth companies amid growing U.S. efforts to secure critical mineral supply chains. Recent news highlights Energy Fuels' Utah plant expansion and ongoing geopolitical focus on reducing China's rare earth dominance.
Outlook remains tied to U.S. industrial policy and rare earth demand, though high volatility (~50% annualized) and China concentration pose risks. Investor sentiment is mixed, balancing strategic importance against execution challenges in building domestic supply chains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →
